Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

or B-VEC), a topical gene therapy for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) who have specific genetic mutations. The recommendation allows for administration in ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the ...

Krystal Biotech (NASDAQ:KRYS) has received a positive recommendation from the European Medicines Agency's Committee for ...

has issued a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) Dystrophic epidermolysis bullosa is a genetic ...

More info A Dublin girl born with the most severe form of butterfly skin is excited as she prepares to go to secondary school ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Suggested remit: To appraise the clinical and cost effectiveness of Beremagene geperpavec within its marketing authorisation for treating skin wounds assocatied with dystrophic epidermolysis bullosa.

for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP's positive ...